Ethics of Early Clinical Trials of Bio-Artificial Organs.
Transpl Int
; 35: 10621, 2022.
Article
em En
| MEDLINE
| ID: mdl-35874305
ABSTRACT
Regenerative medicine is the new frontier in the field of organ transplantation. Research groups around the world are using regenerative medicine technologies to develop bio-artificial organs for transplantation into human patients. While most of this research is still at the preclinical stage, bio-artificial organ technologies are gearing up for first-in-human clinical trials in the not-too-distant future. What are the ethical conditions under which early-phase clinical research of bio-artificial organs can be conducted safely and responsibly? What lessons can be learned from prior experiences with early-phase clinical trials in adjacent fields of research? This is a Meeting Report of an online international workshop organised in the context of the Horizon 2020-funded VANGUARD project, which is developing a bio-artificial pancreas for the treatment of patients with type 1 diabetes.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Órgãos Artificiais
/
Ensaios Clínicos como Assunto
Aspecto:
Ethics
Limite:
Humans
Idioma:
En
Revista:
Transpl Int
Ano de publicação:
2022
Tipo de documento:
Article